PASITHEA THERAPEUTICS CORP. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
PASITHEA THERAPEUTICS CORP. (KTTA) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $315.08 thousand as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2026-08-14
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $315.08K.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $472.62K.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $157.54K.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $315.08K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $315.08K 10-Q · filed 2026-08-14 |
| 2026-03-31 | $472.62K 10-Q · filed 2026-05-15 |
| 2025-09-30 | $157.54K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $315.08K 10-Q · filed 2025-08-14 |
| 2025-03-31 | $472.62K 10-Q · filed 2025-05-15 |
| 2024-09-30 | $157.54K 10-Q · filed 2024-11-13 |
| 2024-06-30 | $315.08K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $472.62K 10-Q · filed 2024-05-14 |
| 2023-09-30 | $157.54K 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Rocket One Inc. (RKTO) | United States | $0.019B |